Show more Model based approaches, integrating physiological parameters or linking exposure with response, are powerful tools to quantify and evaluate the impact of genetic differences that are reflected as variability of drug exposure and/or clinical response(s). Evaluating the potential impact of genetic differences early during. The model was used to quantify the optimal dose and regime (Single treatment/genotyped-based or titrated based upon response) for future clinical trials. Population pharmacokinetic and pharmacodynamic models were developed to evaluate the relationship between exposure differences resulting from UGT2B15 genotype and their effects on both fasting plasma glucose and glycosylated haemoglobin for the type 2 diabetes drug, Sipoglitazar_. This thesis _Pharmacogenomics in Drug Development: Implementation and Application of PKPD Model Based Approaches_ focused on genotype differences in explaining inter-individual variability in drug metabolism and clinical response.
![nonmem 3 new residual variability models eta on sigma nonmem 3 new residual variability models eta on sigma](https://cyberleninka.org/viewer_images/319318/f/1.png)
Pharmacogenomics in drug development : implementation and application of PKPD model based approaches Doctoral Thesis Model based approaches, integrating physiological parameters or linking exposure with response, are powerful tools to quantify and evaluate the impact of genetic differences that are reflected as variability of drug exposure and/or clinical response(s).